Compounds > 6-chloro-1-4-dihydro-4-oxo-1-(beta-d-ribofuranosyl)quinoline-3-carboxylic-acid

6-chloro-1-4-dihydro-4-oxo-1-(beta-d-ribofuranosyl)quinoline-3-carboxylic-acid and benzonidazole

6-chloro-1-4-dihydro-4-oxo-1-(beta-d-ribofuranosyl)quinoline-3-carboxylic-acid has been researched along with benzonidazole* in 1 studies

*benzonidazole: used in treatment of Chagas' disease [MeSH]

Other Studies

1 other study(ies) available for 6-chloro-1-4-dihydro-4-oxo-1-(beta-d-ribofuranosyl)quinoline-3-carboxylic-acid and benzonidazole

Article	Year
Molecular design, synthesis and biological evaluation of 1,4-dihydro-4-oxoquinoline ribonucleosides as TcGAPDH inhibitors with trypanocidal activity. Bioorganic & medicinal chemistry letters, 2013, Aug-15, Volume: 23, Issue:16 The 1,4-dihydro-4-oxoquinoline ribonucleoside, Neq135, is the first low micromolar trypanosomatidae inhibitor to show good ligand efficiency (0.28 kcal mol(-1)atom(-1)) and good ligand lipophilicity efficiency (0.37 kcal mol(-1)atom(-1)) when acting against Trypanosoma cruzi glyceraldehyde 3-phosphate dehydrogenase (TcGAPDH). This and other six ribonucleosides were synthesized using our in-house technology, and assayed against the GAPDH NAD(+) site using isothermal titration calorimetry (ITC). Compound Neq135 had acceptable in vitro cytotoxicity, inhibited TcGAPDH with a Ki(app) value of 16 μM and killed the trypomastigote form of Trypanosoma cruzi Tulahuen strain with a concentration similar to that displayed by the control drug benznidazole. Neq135 is tenfold lower kinetic affinity against hGAPDH and does not kill Balb-c fibroblast nor spleen mouse cells. These results emphasize the possibility of integrating ligand- and target-based designs to uncover potent and selective TcGAPDH inhibitors that expands the opportunity for further medicinal chemistry endeavor towards NAD(+) TcGAPDH site. Topics: 4-Quinolones; Animals; BALB 3T3 Cells; Drug Design; Fibroblasts; Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating); Inhibitory Concentration 50; Mice; Nitroimidazoles; Ribonucleosides; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma cruzi	2013

Article

Year

Molecular design, synthesis and biological evaluation of 1,4-dihydro-4-oxoquinoline ribonucleosides as TcGAPDH inhibitors with trypanocidal activity.

Bioorganic & medicinal chemistry letters, 2013, Aug-15, Volume: 23, Issue:16

The 1,4-dihydro-4-oxoquinoline ribonucleoside, Neq135, is the first low micromolar trypanosomatidae inhibitor to show good ligand efficiency (0.28 kcal mol(-1)atom(-1)) and good ligand lipophilicity efficiency (0.37 kcal mol(-1)atom(-1)) when acting against Trypanosoma cruzi glyceraldehyde 3-phosphate dehydrogenase (TcGAPDH). This and other six ribonucleosides were synthesized using our in-house technology, and assayed against the GAPDH NAD(+) site using isothermal titration calorimetry (ITC). Compound Neq135 had acceptable in vitro cytotoxicity, inhibited TcGAPDH with a Ki(app) value of 16 μM and killed the trypomastigote form of Trypanosoma cruzi Tulahuen strain with a concentration similar to that displayed by the control drug benznidazole. Neq135 is tenfold lower kinetic affinity against hGAPDH and does not kill Balb-c fibroblast nor spleen mouse cells. These results emphasize the possibility of integrating ligand- and target-based designs to uncover potent and selective TcGAPDH inhibitors that expands the opportunity for further medicinal chemistry endeavor towards NAD(+) TcGAPDH site.

Topics: 4-Quinolones; Animals; BALB 3T3 Cells; Drug Design; Fibroblasts; Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating); Inhibitory Concentration 50; Mice; Nitroimidazoles; Ribonucleosides; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma cruzi

2013